Entries by CAPTIS

Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy

The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or The post Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy appeared first on Pharmaceutical Business review.

FDA approves TEPEZZA for the treatment of thyroid eye disease

TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), The post FDA approves TEPEZZA for the treatment of thyroid eye disease appeared first on Pharmaceutical Business review.